Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) plus Imprime PGG (Imprime) plus bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).

被引：1
|
作者：
Fakih, Marwan
Cleary, James M.
Hong, Yong Sang
Kim, Tae-You
Safyan, Rachael A.
Allen, Simon
Bailey, Lorna
Cha, Edward
Lenain, Christelle
Lu, Danny
Schulze, Jochen
Shemesh, Colby S.
Zimmermann, Stefan
机构：
[1] City Hope Comprehens Med Ctr, Duarte, CA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[4] Seoul Natl Univ Hosp, Seoul, South Korea
[5] Columbia Univ, Irving Med Ctr, New York, NY USA
[6] Genentech Inc, San Francisco, CA 94080 USA
[7] Roche Prod Ltd, Welwyn Garden City, England
[8] F Hoffmann La Roche Ltd, Basel, Switzerland
[9] Hoffmann La Roche Ltd, Mississauga, ON, Canada
[10] Univ Hosp Lausanne, Immunooncol Serv, Dept Oncol, Lausanne, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3559
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3559
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer.
    Desai, Jayesh
    Fakih, Marwan
    Pedersen, Katrina Sophia
    Hong, Yong Sang
    Segal, Neil Howard
    Allen, Simon
    Bailey, Lorna
    Lenain, Christelle
    Lu, Danny
    Sayyed, Pakeeza Zahra
    Schulze, Jochen
    Cecchini, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [2] PHASE IB/II OPEN-LABEL, RANDOMIZED EVALUATION OF ATEZOLIZUMAB (ATEZO) plus SELICRELUMAB (SELI) plus GEMCITABINE plus NAB-PACLITAXEL (GEM plus NABP) OR BEVACIZUMAB (BEV) VS CONTROL IN MORPHEUS-PDAC, -TNBC AND -CRC
    Manji, Gulam
    Bahary, Nathan
    Chung, Vincent
    Dalenc, Florence
    Ducreux, Michel
    Gomez-Roca, Carlos
    Im, Seock-Ah
    Kortmansky, Jeremy
    Lacy, Jill
    Segal, Neil
    Tredan, Olivier
    Cirovic, Olivera
    DuPree, Kelly
    Lenain, Christelle
    Lu, Danny
    Robert, Lidia
    Xu, Jeffrey
    Zhang, Xiaosong
    Kim, Sung-Bae
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A157 - A158
  • [3] A phase Ib study of the safety and efficacy of atezolizumab (atezo) plus bevacizumab (bev) plus cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)
    Bendell, J.
    Lieu, C.
    Raghav, K. P. S.
    Argiles, G.
    Cubillo, A.
    Qu, X.
    Yan, Y.
    Merchant, M.
    Zeuner, H.
    Gallo, J. D.
    Segal, N. H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Phase Ib/II, global, open-label, randomized evaluation of atezolizumab (atezo) plus etrumadenant (etruma) plus chemotherapy (chemo) vs chemo alone in MORPHEUS-PDAC
    Kim, Kyu-Pyo
    Sarvise, Mariano Ponz
    Macarulla, Teresa
    Alistar, Angela
    O'Reilly, Eileen
    Boakye, Mathew
    Prizant, Hen
    Xu, Trista
    Young, Fiona
    Lau, Janet
    Oh, Do-Youn
    Lacy, Jill
    CANCER RESEARCH, 2024, 84 (07)
  • [5] Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Bocobo, Andrea Grace
    Wang, Renee
    Behr, Spencer
    Carnevale, Julia C.
    Cinar, Pelin
    Collisson, Eric Andrew
    Fong, Lawrence
    Keenan, Bridget P.
    Kidder, Wesley Allen
    Ko, Andrew H.
    Kolli, Kanti Pallav
    Kennedy, Megan
    Laffan, Angela
    Piawah, Sorbarikor
    Pollak, Marin
    Schwartz, Gabriel
    Whitman, Julia
    Zhang, Li
    Van Loon, Katherine
    Atreya, Chloe Evelyn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC)
    Hochster, Howard S.
    Bendell, Johanna C.
    Cleary, James M.
    Foster, Paul
    Zhang, Wei
    He, Xian
    Hernandez, Genevive
    Iizuka, Koho
    Eckhardt, S. Gail
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [7] Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) plus linagliptin (lina) vs ramucirumab (ram) plus paclitaxel (pac) in MORPHEUS-gastric cancer
    Lee, J.
    Ajani, J. A.
    Chung, H. C.
    Kang, Y-K.
    Iqbal, S.
    Allen, S.
    Al-Sakaff, N.
    Decalf, J.
    Li, S.
    Pintoffl, J.
    Sayyed, P.
    Bang, Y-J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1047 - S1047
  • [8] FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO
    Cremolini, C.
    Rossini, D.
    Antoniotti, C.
    Pietrantonio, F.
    Lonardi, S.
    Salvatore, L.
    Marmorino, F.
    Borelli, B.
    Ambrosini, M.
    Barsotti, G.
    Di Stefano, B.
    Masi, G.
    Boccaccino, A.
    Tamberi, S.
    Tamburini, E.
    Frassineti, L. G.
    Simionato, F.
    Fontanini, G.
    Boni, L.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1294 - S1295
  • [9] Efficacy and safety of cobimetinib (cobi) and atezolizumab (atezo) in an expanded phase 1b study of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)
    Desai, J.
    Hong, Y. S.
    Kim, J. E.
    Kim, T. W.
    Han, S. W.
    Bang, Y-J.
    Chee, C. E.
    Heong, V. Y. M.
    Mcree, A.
    Chow, L. Q.
    Kwak, E. L.
    Infante, J. R.
    Wallin, J.
    Das Thakur, M.
    Mwawasi, G.
    Foster, P.
    Cha, E.
    Bendell, J. C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] A phase II, multicenter, open-label study of polyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301).
    Hubbard, Joleen M.
    Ahn, Daniel H.
    Jones, Jeremy Clifton
    Zhu, Mojun
    Wittenberger, Kathleen
    Csiszovszki, Zsolt
    Somogyi, Eszter
    Lorincz, Orsolya
    Molnar, Levente
    Toth, Jozsef
    Youssoufian, Hagop
    Toke, Eniko Rita
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345